Harnessing Optimism and Perseverance in the Face of Long COVID-Español
Public ClinicalTrials.gov record NCT07216040. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Harnessing Optimism and Perseverance in the Face of Long COVID~Español (HOPE-LC~Español)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Harnessing Optimism and Perseverance in the Face of Long COVID (HOPE-LC) program, created by Drs. Eric Watson and Amelia Hicks, is a group therapy model designed to foster resilience, adjustment, and coping skills for those living with chronic Long COVID. HOPE-LC\~Español provides a culturally and linguistically adapted version for Spanish-speaking individuals in Queens, developed with input from Spanish-speaking clinicians, Long COVID experts, and people with lived experience. Partnering with H+H/Elmhurst and H+H/Queens, the project aims to recruit 25 participants and evaluate program feasibility and preliminary efficacy.
Study identification
- NCT ID
- NCT07216040
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2026
- Primary completion
- Aug 30, 2026
- Completion
- Aug 30, 2026
- Last update posted
- Apr 22, 2026
2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brain Injury Research Center | New York | New York | 10029 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Post-Acute COVID-19 Syndrome trials
Other public records listing Post-Acute COVID-19 Syndrome. Sorted by last update posted; newest first. Not a recommendation.
- NCT07388550: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) Not yet recruiting
- NCT05421208: Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome Active, not recruiting
- NCT05977179: Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome Recruiting
- NCT05676008: A Study of Positive Emotions With Long COVID-19 Active, not recruiting
- NCT05705193: Brain-Training Treatment for Long COVID in Older Adults Active, not recruiting
- NCT05747534: AT1001 for the Treatment of Long COVID Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07216040, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 22, 2026 · Synced Jul 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07216040 live on ClinicalTrials.gov.